Haleon plc announced on October 1, 2024, that it will purchase 60,526,315 shares from Pfizer at £3.80 each, totaling approximately £230 million; this marks a reduction of Pfizer's stake in Haleon from 22.6% to 15.0%. This purchase supports Haleon's commitment to return £500 million to shareholders through buybacks this year.